Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography

Angiology

Volumn 61, Issue 7, 2010, Pages 711-714

  Özhan, Hakan ^a   Erden, Ismail ^a   Ordu, Serkan ^a   Aydin, Mesut ^a   Caglar, Onur ^a   Basar, Cengiz ^a   Yalcin, Subhan ^a   Alemdar, Recai ^a  

^a DUZCE UNIVERSITY   (Turkey)

Author keywords

atorvastatin; contrast induced nephropathy; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; ATORVASTATIN; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CONTRAST MEDIUM; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CHEMICAL ANALYSIS; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; ACUTE KIDNEY INJURY; BLOOD; CHEMICALLY INDUCED; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ACETYLCYSTEINE; ACUTE KIDNEY INJURY; ADULT; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES;

EID: 77956467157     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710364216     Document Type: Article

References (23)

1. Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart J. 2008 ; 155 (3). 499.e1-499.e8.
2. McCullough PA, Wolyn R., Rocher LL, Levin RN, OĝNeill WW Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997 ; 103 (5). 368-375.
3. Tepel M., van der Giet M., Schwarzfeld C., Laufer U., Liermann D., Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000 ; 343 (3). 180-184.
4. Stoll LL, McCormick ML, Denning GM, Weintraub NL Antioxidant effects of statins. Drugs Today. 2004 ; 40 (12). 975-990.
5. Gueler F., Rong S., Park JK, et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol. 2002 ; 13 (9). 2288-2298.
6. Khanal S., Attallah N., Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005 ; 118 (8). 843-849.
7. Attallah N., Yassine L., Musial J., Yee J., Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004 ; 62 (4). 273-278.
8. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16 (1). 31-41.
9. Murphy SW, Barrett BJ, Parfrey PS Contrast nephropathy. J Am Soc Nephrol. 2000 ; 11 (1). 177-182.
10. Lameire N., Van Biesen W., Vanholder R. Acute renal failure. Lancet. 2005 ; 365 (9457). 417-430.
11. Tepel M., Aspelin P., Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006 ; 113 (14). 1799-1806.
12. Liu R., Nair D., Ix J., Moore DH, Bent S. N-Acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. J Gen Intern Med. 2005 ; 20 (2). 193-200.
13. Duong MH, Mackenzie TA, Malenka DJ N-Acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv. 2005 ; 64 (4). 471-479.
14. Patti G., Nusca A., Chello M., et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008 ; 101 (3). 279-285.
15. Wassmann S., Faul A., Hennen B., Scheller B., BÖhm M., Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res. 2003 ; 93 (9). e98 - e103.
16. Schaefer EJ, McNamara JR, Asztalos BF, et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005 ; 95 (9). 1025-1032.
17. Xinwei J., Xianghua F., Jing Z., et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009 ; 104 (4). 519-524.
18. Yoshida S., Kamihata H., Nakamura S., et al. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol. 2009 ; 54 (2). 192-198.
19. Goldenberg I., Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. Can Med Assoc. J. 2005 ; 172 (11). 1461-1471.
20. Bonetti PO, Lerman LO, Napoli C., Lerman A. Statin effects beyond lipid lowering are they clinically relevant ? Eur Heart J. 2003 ; 24 (3). 225-248.
21. Chello M., Goffredo C., Patti G., et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cardiothorac Surg. 2005 ; 28 (6). 805-810.
22. Lecian D., Demova H., Lodererova A., et al. Renal effects of HMGCoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press Res. 2006 ; 29 (3). 135-143.
23. Zhou X., Jin YZ, Wang Q., Min R., Zhang XY Efficacy of high dose atorvastatin on preventing contrast-induced nephropathy in patients underwent coronary angiography [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2009 ; 37 (5). 394-396.